Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.

摘要: Abstract Introduction Tadalafil (TAD) 5 mg coadministered with finasteride (FIN) significantly improves lower urinary tract symptoms (LUTS) in men benign prostatic hyperplasia (BPH) and enlargement. However, its effects on erectile/sexual function have yet to be fully described. Aim Assess the of TAD/FIN coadministration (compared placebo [PBO]/FIN) erectile sexual sexually active LUTS enlargement secondary BPH or without baseline comorbid dysfunction (ED). Methods A randomized, double‐blind, PBO‐controlled study 695 (610 active; 450 ED; 404 ED) conducted at 70 sites 13 countries. TAD PBO once daily FIN for 26 weeks. Main Outcome Measures International Index Erectile Function (IIEF) domain single‐item scores; proportions patients who demonstrated minimal clinically important differences (MCIDs) IIEF‐Erectile scores (IIEF‐EF; MCID defined as ≥4‐point improvement); adverse events (AEs). Results Compared PBO/FIN, resulted improvements all IIEF assessed among ED ( P  ≤ 0.002 measures)  ≤ 0.041 measures). larger percentages treated achieved an IIEF‐EF after 4, 12, weeks therapy Conclusions treatment concurrently leads statistically significant is well‐tolerated, regardless presence/absence initiation. Glina S, Roehrborn CG, Esen A, Plekhanov Sorsaburu Henneges C, Buttner H, Viktrup L. Sexual hyperplasia: a 6‐month, placebo‐controlled tadalafil finasteride. J Sex Med 2015;12:129–138.